Morgan Stanley Downgrades Fulcrum Therapeutics (FULC) to Equalweight
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison downgraded Fulcrum Therapeutics (NASDAQ: FULC) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
